Retrogenix Opens Office in Cambridge, Massachusetts
News Jun 20, 2014
Retrogenix has announced that it has opened its first office in the United States - the fastest growing regional market for the UK-based biotech which provides drug target screening services to global pharmaceutical clients.
Retrogenix’s location in Kendall Square, Cambridge, MA, places the company close to its client base and within an internationally-recognized hub for innovative life science research and development.
The company’s technology identifies which of the body’s thousands of cell surface proteins are targeted by drug candidates and other molecules, including natural proteins and viruses. This unique technology has many applications in medical and pharmaceutical research and was recently pivotal in the discovery of a key receptor associated with severe malaria in children, a breakthrough which was reported in the journal Nature.
Retrogenix’s rapid growth is being fuelled by its unrivalled success rates in deconvoluting the targets of molecules identified through phenotypic screening, removing a major bottleneck in drug discovery.
Recent advances in phenotypic screening have created high demand for the rapid identification of novel, disease-relevant, exploitable drug targets along with the information required to prioritize the most promising drug candidates and assess potential toxicity issues at an early stage.
Dr Jim Freeth, Managing Director of Retrogenix, said: “We work with the majority of the world’s top pharmaceutical companies, many of whom have sites in and around the Cambridge area. The success rates we achieve through applying our cell microarray technology are enhanced by close communication and collaboration with clients throughout each project. We now have an ideal base to maintain our existing relationships and offer our unique service to other innovative drug developers.”
Jo Soden, Executive Director, commented: “As the U.S. is currently Retrogenix’s fastest-growing market there is significant momentum to take this natural step in the company’s progression. Globally, there is high demand for Retrogenix’s technology. Our strategic positioning in the centre of a major life sciences hub in Massachusetts will provide us with even greater opportunities to serve our customers and continue to make the drug discovery process more efficient.”
The Retrogenix office is located at the Cambridge Innovation Center, Kendall Square, Cambridge, MA.
Symmetry-breaking Method Opens Way for Bioactive CompoundsNews
EPFL chemists have developed a new catalytic method for symmetry breaking. Published in Angewandte Chemie, the method can help synthesize important building blocks for bioactive compounds such as anticancer drugs.READ MORE
Scientists Report The Development of a Potent New Medicine to Fight AddictionNews
Scientists report the development of a potent new medicine to fight addiction.READ MORE
High-throughput Screening: Microscale Thermophoresis to Characterize HitsNews
A new perspective article details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.READ MORE
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018